CytomX Rehabs, Inc (NASDAQ: CTMX) will launch its fourth-quarter revenues before the opening bell on Monday, March 16.
Experts anticipate the South San Francisco, California-based business to report loss of 9 cents per share, versus a year-ago revenue of 23 cents per share. The agreement price quote for CytomX Rehabs’ quarterly profits is $7.33 million (it reported $38.09 million in 2015), according to Benzinga Pro.
On Nov. 6, CytomX Therapy reported worse-than-expected third-quarter monetary outcomes.
Shares of CytomX Rehabs fell 3.9% to close at $4.68 on Friday.
Benzinga readers can access the current expert scores on the Expert Stock Rankings page. Readers can arrange by stock ticker, business name, expert company, score modification or other variables.
Let’s take a look at how Benzinga’s most-accurate experts have actually ranked the business in the current duration.
Thinking about purchasing CTMX stock? Here’s what experts believe:
Picture through Shutterstock
Market News and Data gave you by Benzinga APIs
To include Benzinga News as your favored source on Google, click on this link.